Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors

Area of Science:

• Neuro-oncology
• Cancer Immunology
• Immunotherapy

Background:

• Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, with limited survival rates despite current treatments.
• The median survival for GBM patients is approximately 14 months, highlighting the urgent need for novel therapeutic strategies.
• Harnessing the immune system through immunotherapy presents a potential avenue for durable and targeted cancer treatment.

Purpose of the Study:

• To explore the potential of immunotherapy for treating glioblastoma.
• To identify key challenges in developing effective immunotherapeutic regimens for GBM.
• To emphasize the importance of addressing tumor-induced immunosuppression in GBM treatment.

Main Methods:

• Review of current therapeutic limitations for GBM.
• Exploration of immunotherapy principles and applications in oncology.
• Analysis of tumor immune evasion mechanisms in GBM.

Main Results:

• GBM remains a significant clinical challenge with poor patient outcomes.
• Immunotherapy holds promise for targeted cancer treatment.
• Tumor cells employ mechanisms to evade immune detection and elimination.

Conclusions:

• Novel treatment strategies are essential to improve GBM patient outcomes.
• Overcoming tumor-induced immunosuppression is critical for successful immunotherapy in GBM.
• Targeting immune checkpoints represents a promising approach for future GBM immunotherapeutic regimens.